Welcome to our dedicated page for DarioHealth SEC filings (Ticker: DRIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DarioHealth Corp. filings document the regulatory record of a Nasdaq-listed digital health company with common stock registered under the Exchange Act. Recent 8-K reports cover material agreements, including equity offering arrangements, securities purchase agreements and amendments to credit facilities, along with related capital-structure disclosures involving common stock, preferred stock and pre-funded warrants.
The company’s filings also record governance and charter matters, including amendments to its certificate of incorporation, preferred stock designation changes, annual meeting voting results and board appointments. These disclosures frame DRIO’s formal reporting around financing activity, security-holder rights, corporate governance and material events tied to its digital therapeutics business.
DarioHealth Corp. director Dennis Matheis purchased 14,430 shares of Common Stock at $6.93 per share on July 23, 2026, under a Securities Purchase Agreement dated July 22, 2026. Earlier, on August 12, 2024, 50 shares of his Series B-2 Preferred Stock automatically converted into 965 post–reverse-split common shares, subject to a 19.99% beneficial ownership blocker, and he beneficially owned 28,596 common shares immediately after that conversion.
DarioHealth Corp. is conducting a registered direct offering of 3,454,559 shares of common stock (or common stock equivalents) at $6.80 per share, for aggregate gross proceeds of approximately $23.5 million before fees and expenses. The securities include 2,437,060 shares of common stock and pre-funded warrants to purchase 1,017,499 shares at $6.7999 per warrant.
Board member Dennis Matheis is purchasing 14,430 additional shares at $6.93 per share. The pre-funded warrants are immediately exercisable but have beneficial ownership limits that generally restrict any holder and its affiliates from exceeding 4.99% or 9.99% ownership without advance notice or, in some cases, shareholder approval.
A.G.P./Alliance Global Partners is acting as sole placement agent, earning a 6.0% cash fee on most gross proceeds (1.0% for certain investors) plus up to $60,000 of reimbursed expenses. For 30 days after closing, the company agreed not to issue most new equity or file additional registration statements, while retaining the ability to use its existing at-the-market facility. Net proceeds are intended for working capital, investments, acquisitions, and general corporate purposes.
DarioHealth Corp. is conducting a registered direct offering under its shelf registration, issuing 2,451,490 shares of common stock and pre-funded warrants to purchase 1,017,499 shares. Common stock is priced at $6.80 per share (with 14,430 shares purchased by a director at $6.93), and the pre-funded warrants are priced at $6.7999 with a de minimis exercise price of $0.0001 per share and no expiration date.
The total offering amount is $23,590,899, with placement agent fees of $482,808 and $23,108,091 in proceeds to the company before expenses; DarioHealth estimates net proceeds of approximately $23.6 million for working capital, investments, acquisitions, and general corporate purposes. The deal is on a “reasonable best efforts” basis with no minimum offering amount, so fewer securities may be sold.
The company reports a going concern uncertainty: as of March 31, 2026 it had $20.0 million in cash, cash equivalents and short-term bank deposits versus $9.4 million in current liabilities and does not believe existing cash will fund planned operations for 12 months without additional capital. The pre-funded warrants include beneficial ownership limits of 4.99% (or 9.99% at holder election) and will not be listed, limiting their liquidity.
DarioHealth Corp. reported that the temporary medical leave of absence of its President and Chief Commercial Officer, Steven Nelson, was extended on July 10, 2026 for an indefinite period. During his leave, the company states that his responsibilities are being handled by members of the senior management team.
DarioHealth Corp. reported a first-quarter 2026 net loss of $8.2M, narrowing from $9.2M a year earlier, as operating expenses declined. Revenue fell 17.3% to $5.6M, mainly due to non-recurring pharma revenue in 2025, partly offset by stronger channel partner and direct-to-consumer sales.
Gross margin stayed broadly stable at about 57%, but the company used $6.0M of cash in operations and ended the quarter with $15.0M in cash and $5.0M in short-term deposits. Management disclosed “substantial doubt” about its ability to continue as a going concern over the next 12 months without additional capital or improved performance.
DarioHealth Corp. director John R. Palumbo has filed an initial Form 3 stating beneficial ownership of 4,500 shares of DarioHealth common stock held directly. This filing reports his starting equity position as a director and does not reflect any recent share purchases or sales.
DarioHealth Corp. has appointed veteran healthcare executive John R. Palumbo to its Board of Directors, effective April 10, 2026. Palumbo, age 75, has more than four decades of operating experience across early-stage ventures and large healthcare companies, including leadership roles at AmerisourceBergen, Allscripts and Shared Medical Systems.
He has guided organizations through transformative growth, including supporting two IPOs and major operational and commercial transformations, and currently serves on several healthcare and digital health boards. Dario expects his deep relationships with health systems, payers and senior healthcare executives to support its next phase of partner-led commercial scaling and expansion across payer, provider and health services markets.
DarioHealth Corp. intends to offer and sell shares of its common stock in an at-the-market offering of up to $20,000,000 of aggregate gross proceeds through A.G.P./Alliance Global Partners as sales agent.
The prospectus supplement states shares may be sold from time to time on Nasdaq or in other market transactions, the Agent may act as agent or principal, and the Agent’s commission may be up to 3.0% of gross sales. The number of shares to be issued will vary with market prices; the prospectus illustration assumes sales at the last reported sale price of $8.11 per share on March 27, 2026.
DarioHealth Corp. entered into a sales agreement with A.G.P./Alliance Global Partners to establish an at-the-market equity program allowing the company to issue and sell up to $20,000,000 of common stock from time to time. A.G.P. will act as sales agent or principal and receive a 3.00% commission on gross proceeds from share sales.
The shares are registered under DarioHealth’s effective Form S-3 shelf registration statement and related ATM prospectus supplement. The company may use net proceeds for commercial, sales and marketing activities, product research and development, mergers and acquisitions, repayment of indebtedness under its credit facility with Callodine Commercial Finance, LLC, and general working capital. DarioHealth can suspend or terminate the program at its discretion, and the agreement also includes customary indemnification, expense reimbursement caps, and termination rights.
DarioHealth Corp. filed a Form S-3 to register up to $100,000,000 of securities. The registration permits the sale, from time to time after effectiveness, of common stock, preferred stock, warrants and units in one or more offerings.
The company states its common stock trades on Nasdaq under the symbol DRIO and discloses 7,300,406 shares of common stock outstanding as of March 19, 2026. The prospectus describes general plan of distribution, use of proceeds, and that specific terms will be provided in prospectus supplements.